[Enhancing survival outcomes in stage â ¢ gastric/esophagogastric junction cancer: a retrospective study of immune checkpoint inhibitors and adjuvant chemotherapy based on real-world data].

Objective: To explore the efficacy of immune checkpoint inhibitors combined with adjuvant chemotherapy in patients with phase III gastric cancer and esophagogastric junction cancer. Methods: This study used a retrospective cohort study method based on real-world data. Clinical data of 403 patients with stage III gastric/esophagogastric junction cancer who underwent gastrectomy followed by adjuvant therapy in the Department of Gastric Surgery at Sun Yat-sen University Cancer Center from January 2020 to December 2023 were retrospectively collected. The study cohort comprised 147 (36.5%) patients with stage IIIA, 130 (32.3%) with stage IIIB, and 126 (31.3%) with stage IIIC gastric/esophagogastric junction cancer. Of them, 15 (3.7%) were HER-2 positive, 25 (6.2%) dMMR, and 22 (5.5%) patients Epstein-Barr virus encoding RNA (EBER) positive. Based on treatment plans, the patients were divided into immune checkpoint inhibitor combined with chemotherapy group (immune therapy group, n=110, 71 males and 39 females, median age 59 years old) and chemotherapy alone group (chemotherapy group, n=293, 186 males and 107 females, median age 60 years old). All patients in the immunotherapy group received immune checkpoint inhibitors targeting the programmed cell death protein-1 (PD-1) and its ligand (PD-L1). Of them, 85 received pembrolizumab, 10 received sintilimab, 8 received tislelizumab, 4 received camrelizumab, 2 received toripalimab, and 1 received pabocizumab. The adjuvant chemotherapy regimens used among the chemotherapy alone group includes SOX regimen (132 cases), XELOX (102 cases), S-1 monotherapy (44 cases), and other regimens (15 cases). The 3-year DFS rate of the two groups was compared, and subgroup analysis was conducted based on different ages, molecular phenotypes, pTNM staging, extranodal infiltration, and tumor length. Results: The median follow-up was 20.5 months (range 3.1~46.3), with a 3-year overall DFS rate of 61.4% for the entire 403 patients. The 3-year DFS rate for the immunotherapy group was 82.7%, higher than the chemotherapy alone group (58.8%), with a statistically significant difference (P=0.021). Multivariate analysis showed that postoperative immunotherapy was a protective factor for DFS (HR=0.352, 95%CI: 0.180~0.685). Subgroup analysis showed that stage IIIC (HR=0.416, 95%CI: 0.184~0.940), aged ≥60 years (HR=0.336, 95%CI: 0.121~0.934) and extranodal invasion (HR=0.378, 95%CI: 0.170~0.839) were associated with benefit from the combined immune adjuvant chemotherapy, while no association was observed for MMR, HER-2 or EBER status. Conclusion: Stage III gastric/esophagogastric junction cancer patients may benefite from postoperative immune checkpoint inhibitor combined with adjuvant chemotherapy in real-world settings.

[Effects of zhengda zhenhua 851 on improvement of memory and fluency of language of kidney deficiency patients].

A study was conducted on the effects of Zhengda Zhenhua 851-R oral liquor on the improvement of memory and fluency of language of patients suffering from Kidney Deficiency and control group. It was found that the treated group did better in memory tests and the index of mental quotient (MQ) was higher than that of control group. They had markedly higher scores in the tests of directional memory which requires one's initiative and the free recollection of pictures. The scores achieved by the treated group were significantly higher than that of control on the tests of the fluency of language and expressions, particularly with words of different categories. The results showed that Zhengda Zhenhua 851-R oral liquor obviously had the function of improving the memory and fluency of language for Kidney Deficiency patients.

[Clinical study of effect of zhengda zhenhua 851-R oral liquor on delayed aging process].

A study was conducted on the effects of Zhengda Zhenhua 851-R (ZZ-851-R) oral liquor on middle aged-old patients with Kidney and Spleen Deficiencies. It was found that ZZ-851-R was able to relieve the symptoms of aging, improve the memory and fluency of speech, the activity of superoxide dismutase (SOD) GSH and GSH-peroxidase (GSH-Px) increased remarkably and serum lipid peroxide (LPO) level decreased significantly. Improvements of immunity, function of the pituitary-gonad axis were also noticed in the study, with decreased E2/T ratio and improved ability of total antioxydation. In summary, the ZZ-851-R has the effect of antisenility, without obvious side-effect.